Blackfan-Diamond Anemia
Also known as: Diamond-Blackfan Anemia, DBA, Congenital Hypoplastic Anemia
Blackfan-Diamond anemia (DBA) is a rare inherited bone marrow failure syndrome characterized by a selective deficiency in erythroid progenitors, leading to a profound anemia. It typically presents in infancy or early childhood. While anemia is the hallmark, DBA is also associated with an increased risk of certain cancers and congenital anomalies.
Imagine your body has a factory that makes red blood cells, which carry oxygen. In DBA, this factory isn't working well, so you don't have enough red blood cells. This makes you tired and pale. Doctors can give you medicine or blood transfusions to help, or even give you a new factory (bone marrow transplant)!
Signs & Symptoms
- Pallor (paleness)
- Lethargy
- Poor feeding
- Short stature
- Craniofacial abnormalities (e.g., webbed neck, cleft palate, small head)
- Thumb abnormalities (e.g., triphalangeal thumb)
- Heart defects
- Increased risk of cancer (e.g., leukemia, osteosarcoma)
Treatment Options
Corticosteroids (e.g., Prednisone)
MODERATELY EFFECTIVERed Blood Cell Transfusions
HIGHLY EFFECTIVEHematopoietic Stem Cell Transplantation (HSCT)
HIGHLY EFFECTIVEIron Chelation Therapy (e.g., Deferoxamine, Deferasirox, Deferiprone)
HIGHLY EFFECTIVELuspatercept
MODERATELY EFFECTIVE Approved 2020Diagnosis
- Complete blood count (CBC) showing macrocytic anemia
- Bone marrow aspiration and biopsy revealing a marked reduction in erythroid precursors
- Erythrocyte adenosine deaminase (eADA) activity: Elevated in most DBA patients
- Ribosomal protein gene mutation analysis (RPS19, RPL5, RPL11, etc.)
- Exclusion of other causes of anemia
History
Blackfan and Diamond independently described the disease in the 1930s, leading to its current name. The genetic basis of DBA began to be elucidated in the late 20th and early 21st centuries with the identification of mutations in ribosomal protein genes.
Recent Breakthroughs
FDA Approves Luspatercept for DBA
Luspatercept, an erythroid maturation agent, was approved by the FDA for the treatment of anemia in adult patients with DBA who have failed or are ineligible for corticosteroid therapy. This provides a new treatment option for patients who are transfusion-dependent or have significant side effects from corticosteroids.
Gene Therapy Approaches in Preclinical Studies
Research is ongoing to develop gene therapy approaches for DBA, aiming to correct the underlying genetic defects in ribosomal protein genes. Preclinical studies have shown promising results in restoring erythropoiesis in animal models.